Ann: Final GvHD Preclinical Report Confirms Treatment Benefit, page-2

Looking positive.
" In animals in which GvHD was induced, the control animals survived for a median of just 24.5 days. However, treatment with CYP-001 markedly prolonged survival with the median survival time being 48 days and 57 days, respectively, in recipients of a single dose or dual doses of CYP-001"

Basically doubled their survival time.

"The mechanistic studies in the second stage of the study generated a substantial body of data, including evidence that CYP-001 treatment significantly decreased the percentage of CD4 and CD8 T cells infiltrating the bone marrow. This finding is noteworthy as infiltration of the bone marrow by CD4/CD8 cells is considered to be a key driver of GvHD, in this pre-clinical model. Full details of these findings will be described in a manuscript submitted to a leading peer-reviewed journal."